Bladder CARE
Commercial- Indications
- Bladder cancer, Upper tract urothelial carcinoma
Company intelligence / Profile preview
Pangea Laboratory
Tustin, California, United Statespangealab.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Pangea Laboratory offers clinically validated non-invasive diagnostic assays. Bladder CARE™ received FDA Breakthrough Device Designation for early detection of bladder cancer and UTUC. PrecisionBIOME™ provides rapid NGS-based identification of pathogens in clinical samples within 48 hours. The company’s products are used both clinically and in research settings.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Diagnostic testNext-generation sequencing (NGS)Non-invasive testing
- Industry
- Molecular Diagnostics
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Pangea Laboratory.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pangea Laboratory.